Marjory A. Bravard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marjory A. Bravard has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Ticona
Hospital Nacional Dos de Mayo. Lima, Perú; Universidad Nacional Mayor de San Marcos. Lima, Perú
2 shared publications - Jon S. Friedland
Affiliation Institute for Infection & Immunity, City St. George’s, University of London, London, United Kingdom
2 shared publications - Jose Wagner Lopez Revilla
Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima 15067, Peru
2 shared publications Luz Caviedes
Laboratorio de Investigación en Enfermedades Infecciosas, Laboratorio de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
2 shared publicationsO'NEil Britton
Mass General Brigham Harvard Medical School Boston Massachusetts USA
2 shared publicationsPeter Dunn
Healthcare Systems Engineering, Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
2 shared publications
Latest Publications
- 26 December 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 20 (2) , e3-e5
A Novel Role to Manage Capacity and Flow in Hospital Medicine
- 26 December 2023
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 20 (2) , e3-e5
A Novel Role to Manage Capacity and Flow in Hospital Medicine
- 14 February 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (7) , 568-575
Impact of a hospital policy to redistribute admission flow across clinical services for capacity relief during COVID‐19 surges
Background: Increased hospital admissions due to COVID‐19 place a disproportionate strain on inpatient general medicine service (GMS) capacity compared to other services.Objective: To study the impact on capacity and safety of a hospital‐wide policy to redistribute admissions from GMS to non‐GMS based on admitting diagnosis during surge periods.Design, Setting, and Participants: Retrospective case‐controlled study at a large teaching hospital. The intervention included adult patients admitted to general care wards during two surge periods (January–February 2021 and 2022) whose admission diagnosis was impacted by the policy. The control cohort included admissions during a matched number of days preceding the intervention.Main Outcomes and Measures: Capacity measures included average daily admissions and hospital census occupied on GMS. Safety measures included length of stay (LOS) and adverse outcomes (death, rapid response, floor‐to‐intensive care unit transfer, and 30‐day readmission).Results: In the control cohort, there were 365 encounters with 299 (81.9%) GMS admissions and 66 (18.1%) non‐GMS versus the intervention with 384 encounters, including 94 (24.5%) GMS admissions and 290 (75.5%) non‐GMS (p < .001). The average GMS census decreased from 17.9 and 21.5 during control periods to 5.5 and 8.5 during intervention periods. An interrupted time series analysis confirmed a decrease in GMS daily admissions (p < .001) and average daily hospital census (p = .014; p < .001). There were no significant differences in LOS (5.9 vs. 5.9 days, p = .059) or adverse outcomes (53, 14.5% vs. 63, 16.4%; p = .482).Conclusion: Admission redistribution based on diagnosis is a safe lever to reduce capacity strain on GMS during COVID‐19 surges.
- 14 February 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (7) , 568-575
Impact of a hospital policy to redistribute admission flow across clinical services for capacity relief during COVID‐19 surges
Background: Increased hospital admissions due to COVID‐19 place a disproportionate strain on inpatient general medicine service (GMS) capacity compared to other services.Objective: To study the impact on capacity and safety of a hospital‐wide policy to redistribute admissions from GMS to non‐GMS based on admitting diagnosis during surge periods.Design, Setting, and Participants: Retrospective case‐controlled study at a large teaching hospital. The intervention included adult patients admitted to general care wards during two surge periods (January–February 2021 and 2022) whose admission diagnosis was impacted by the policy. The control cohort included admissions during a matched number of days preceding the intervention.Main Outcomes and Measures: Capacity measures included average daily admissions and hospital census occupied on GMS. Safety measures included length of stay (LOS) and adverse outcomes (death, rapid response, floor‐to‐intensive care unit transfer, and 30‐day readmission).Results: In the control cohort, there were 365 encounters with 299 (81.9%) GMS admissions and 66 (18.1%) non‐GMS versus the intervention with 384 encounters, including 94 (24.5%) GMS admissions and 290 (75.5%) non‐GMS (p < .001). The average GMS census decreased from 17.9 and 21.5 during control periods to 5.5 and 8.5 during intervention periods. An interrupted time series analysis confirmed a decrease in GMS daily admissions (p < .001) and average daily hospital census (p = .014; p < .001). There were no significant differences in LOS (5.9 vs. 5.9 days, p = .059) or adverse outcomes (53, 14.5% vs. 63, 16.4%; p = .482).Conclusion: Admission redistribution based on diagnosis is a safe lever to reduce capacity strain on GMS during COVID‐19 surges.
- 1 November 2022
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 49 (4) , 181-188
The Gap Between Daily Hospital Bed Supply and Demand: Design, Implementation, and Impact of Data-Driven Pre-Noon Discharge Targets
- 1 November 2022
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 49 (4) , 181-188
The Gap Between Daily Hospital Bed Supply and Demand: Design, Implementation, and Impact of Data-Driven Pre-Noon Discharge Targets
- Open Access
- 6 June 2018
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 98 (6) , 1637-1639
Exhaled Nitric Oxide is Not a Biomarker for Pulmonary Tuberculosis
To reduce transmission of tuberculosis (TB) in resource-limited countries where TB remains a major cause of mortality, novel diagnostic tools are urgently needed. We evaluated the fractional concentration of exhaled nitric oxide (FeNO) as an easily measured, noninvasive potential biomarker for diagnosis and monitoring of treatment response in participants with pulmonary TB including multidrug resistant–TB in Lima, Peru. In a longitudinal study however, we found no differences in baseline median FeNO levels between 38 TB participants and 93 age-matched controls (13 parts per billion [ppb] [interquartile range (IQR) = 8–26] versus 15 ppb [IQR = 12–24]), and there was no change over 60 days of treatment (15 ppb [IQR = 10–19] at day 60). Taking this and previous evidence together, we conclude FeNO is not of value in either the diagnosis of pulmonary TB or as a marker of treatment response.
- 6 June 2018
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 98 (6) , 1637-1639
Open AccessExhaled Nitric Oxide is Not a Biomarker for Pulmonary Tuberculosis
To reduce transmission of tuberculosis (TB) in resource-limited countries where TB remains a major cause of mortality, novel diagnostic tools are urgently needed. We evaluated the fractional concentration of exhaled nitric oxide (FeNO) as an easily measured, noninvasive potential biomarker for diagnosis and monitoring of treatment response in participants with pulmonary TB including multidrug resistant–TB in Lima, Peru. In a longitudinal study however, we found no differences in baseline median FeNO levels between 38 TB participants and 93 age-matched controls (13 parts per billion [ppb] [interquartile range (IQR) = 8–26] versus 15 ppb [IQR = 12–24]), and there was no change over 60 days of treatment (15 ppb [IQR = 10–19] at day 60). Taking this and previous evidence together, we conclude FeNO is not of value in either the diagnosis of pulmonary TB or as a marker of treatment response.